Cargando…

A Multidisciplinary Diagnostic Approach Reveals a Higher Prevalence of Indolent Systemic Mastocytosis: 15-Years’ Experience of the GISM Network

SIMPLE SUMMARY: The approach of the Interdisciplinary Group for Study of Mastocytosis (GISM) of Verona, based on a regional network of clinical specialists and expert pathologists, with the availability of sensitive molecular and flow-cytometry diagnostic techniques, allowed the discovery of a highe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zanotti, Roberta, Bonifacio, Massimiliano, Isolan, Cecilia, Tanasi, Ilaria, Crosera, Lara, Olivieri, Francesco, Orsolini, Giovanni, Schena, Donatella, Bonadonna, Patrizia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699786/ https://www.ncbi.nlm.nih.gov/pubmed/34944999 http://dx.doi.org/10.3390/cancers13246380

Ejemplares similares

Systemic Mastocytosis: Multidisciplinary Approach
por: Zanotti, Roberta, et al.
Publicado: (2021)

Bone Marrow Mastocytosis: A Diagnostic Challenge
por: Zanotti, Roberta, et al.
Publicado: (2021)

The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis
por: Mannelli, Francesco, et al.
Publicado: (2023)

Non-steroidal anti-inflammatory drug-induced anaphylaxis infrequent in 388 patients with mastocytosis: A two-center retrospective cohort study
por: Bonadonna, Patrizia, et al.
Publicado: (2022)

State of the Art and New Trends from the 2022 Gism Annual Meeting
por: Ferrero, Ivana, et al.
Publicado: (2023)

Multiple large osteolytic lesions in a patient with systemic mastocytosis: a challenging diagnosis
por: Bonifacio, Massimiliano, et al.
Publicado: (2017)

Efficacy of Omalizumab in Indolent Systemic Mastocytosis
por: Slapnicar, Calum, et al.
Publicado: (2019)

Treatment of Indolent and Advanced Systemic Mastocytosis
por: Buonomo, Alessandro, et al.
Publicado: (2022)

Indolent systemic mastocytosis in a patient with ileocolitis
por: Chrysakopoulos, Georgios, et al.
Publicado: (2014)

Delayed Diagnosis of Adult Indolent Systemic Mastocytosis
por: Mikkelsen, Carsten Sauer, et al.
Publicado: (2014)

Indolent systemic mastocytosis mimicking Crohn’s disease
por: Hadjivasilis, Alexandros, et al.
Publicado: (2019)

Indolent Systemic Mastocytosis Manifesting as Protracted Anaphylactic Shock
por: Chatterjee, Manidipam, et al.
Publicado: (2018)

Primary cicatricial alopecia associated with systemic indolent mastocytosis
por: Prasad, Sonya, et al.
Publicado: (2020)

DNA methylation profile in patients with indolent systemic mastocytosis
por: Górska, Aleksandra, et al.
Publicado: (2021)

Indolent systemic mastocytosis associated with light chain deposition disease
por: Sasaki, Kotaro, et al.
Publicado: (2012)

Diagnosis of indolent systemic mastocytosis in a patient with “seborrheic keratosis”
por: Moshref Razavi, Habib, et al.
Publicado: (2022)

Clinical Outcomes of Adults with Systemic Mastocytosis: A 15-Year Multidisciplinary Experience
por: Ungerstedt, Johanna, et al.
Publicado: (2022)

Venom immunotherapy in indolent systemic mastocytosis with high serum tryptase level
por: Selcuk, Ali, et al.
Publicado: (2021)

Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches
por: Valent, Peter, et al.
Publicado: (2019)

Gastrointestinal Manifestations in Systemic Mastocytosis: The Need of a Multidisciplinary Approach
por: Zanelli, Magda, et al.
Publicado: (2021)

Pancreatic neuroendocrine tumor presenting in indolent systemic mastocytosis: A case report
por: Sacco, Keith, et al.
Publicado: (2020)

Genome-Wide DNA Methylation and Gene Expression in Patients with Indolent Systemic Mastocytosis
por: Górska, Aleksandra, et al.
Publicado: (2023)

COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)
por: Bonadonna, Patrizia, et al.
Publicado: (2021)

Serum Tryptase Monitoring in Indolent Systemic Mastocytosis: Association with Disease Features and Patient Outcome
por: Matito, Almudena, et al.
Publicado: (2013)

SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted
por: Mancini, Manuela, et al.
Publicado: (2023)

COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms
por: Giannetti, Matthew P., et al.
Publicado: (2021)

Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel
por: Velloso, Elvira D. Rodrigues Pereira, et al.
Publicado: (2022)

Delayed Diagnosis of Indolent Systemic Mastocytosis as the Cause of Unexplained Skin Rash: A Case Report
por: Alshurafa, Awni, et al.
Publicado: (2023)

Indolent systemic mastocytosis and aleukemic mast cell leukemia: Subtle diagnostic differences with distinct management approaches
por: Paiva, Marcelo L., et al.
Publicado: (2023)

P993: SETD2 IS A BONA FIDE TUMOR SUPPRESSOR IN SYSTEMIC MASTOCYTOSIS
por: Mancini, M., et al.
Publicado: (2022)

Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF(©)
por: Taylor, Fiona, et al.
Publicado: (2021)

Melanoma and Mastocytosis
por: Vojvodic, Aleksandra, et al.
Publicado: (2019)

Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study
por: Padilla, Brad, et al.
Publicado: (2021)

The Number of MRGPRX2-Expressing Cells Is Increased in Skin Lesions of Patients With Indolent Systemic Mastocytosis, But Is Not Linked to Symptom Severity
por: Pyatilova, Polina, et al.
Publicado: (2022)

Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions
por: Valent, Peter, et al.
Publicado: (2020)

Mastocytosis and systemic sclerosis: a clinical association
por: Bagnato, Gianluca, et al.
Publicado: (2016)

Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis
por: Kluin-Nelemans, Hanneke C., et al.
Publicado: (2021)

Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF(©)) and determination of a threshold score for moderate symptoms
por: Shields, Alan L., et al.
Publicado: (2023)

P1017: REDUCTIONS IN INDOLENT SYSTEMIC MASTOCYTOSIS BIOMARKER BURDEN WITH AVAPRITINIB IN THE REGISTRATIONAL, DOUBLE-BLIND PLACEBO-CONTROLLED PIONEER TRIAL
por: Gotlib, Jason, et al.
Publicado: (2023)

Pediatric Mastocytosis: An Update
por: Giona, Fiorina
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n01jd0f7uif2th6t3g1tjnnidt